Bromhexin 12 mg, 20 tablets, Laropharm

Bromhexine 12 mg, 20 tablets, Laropharm

Bromhexin Laropharm 12 mg tablets is a mucolytic drug that increases the amount of expectorated sputum and decreases its viscosity. Improves bronchial transport, reduces cough and eases breathing.

Therapeutic indications:

Fluidifier of bronchial secretions during acute and chronic bronchopulmonary diseases accompanied by viscous secretions: acute bronchitis, chronic bronchitis, tracheobronchitis, exacerbations of chronic obstructive bronchopneumopathy, bronchiectasis, pneumoconiosis.

Composition:

One tablet contains bromhexine hydrochloride 12 mg and excipients.

Doses and method of administration:

Bromhexin Laropharm 12 mg tablets is indicated for adults, adolescents and children over 10 years of age.

• Adults: the usual dose is 12 mg bromhexine hydrochloride (1 Bromhexin Laropharm tablet) three times a day.
• Children over 10 years of age : the usual dose is 12 mg bromhexine hydrochloride (1 Bromhexin Laropharm tablet) twice a day.
• Children aged between 6 and 10 years : It is recommended for this age group to administer other pharmaceutical forms, with lower concentrations of active substance.

Bromhexin Laropharm 12 mg tablets are administered orally, after meals. During bromhexine therapy, adequate fluid consumption is recommended, considering that this improves the mucolytic action of bromhexine on secretions.

Do not use Bromhexin Laropharm 12 mg tablets for more than 4-5 days, unless it has been recommended by your doctor.

Contraindications:

• Hypersensitivity to bromhexine or any of the product's components.
• Severe renal failure (accumulation of metabolites).
• Children under 6 years old.

Precautions:

Because it contains lactose, patients with rare hereditary disorders of galactose intolerance, lactase deficiency or glucose-galactose malabsorption syndrome should not use this medicine.

Special warnings:

Pregnancy: In general, it is not recommended to take during pregnancy.

Bromhexine crosses the feto-placental barrier. Data on the teratogenic or embryotoxic effect from the use of bromhexine in pregnant women are limited.

Bromhexine hydrochloride is administered in the first trimester of pregnancy only under the strict indication of the doctor.

Breastfeeding: Since bromhexine hydrochloride is excreted in breast milk, it is not recommended to take it during breastfeeding or it is recommended to stop breastfeeding, taking into account the benefit/risk ratio.

Driving and using machines: Adverse reactions such as vertigo, headache, which may influence the ability to drive vehicles or use machines, have been reported rarely, associated with the use of bromhexine.

Presentation:

20 tablets